Metabolomic signature of exposure and response to citalopram/escitalopram in depressed outpatients.

ABSTRACT: Metabolomics provides valuable tools for the study of drug effects, unraveling the mechanism of action and variation in response due to treatment. In this study we used electrochemistry-based targeted metabolomics to gain insights into the mechanisms of action of escitalopram/citalopram focusing on a set of 31 metabolites from neurotransmitter-related pathways. Overall, 290 unipolar patients with major depressive disorder were profiled at baseline, after 4 and 8 weeks of drug treatment. The 17-item Hamilton Depression Rating Scale (HRSD₁₇) scores gauged depressive symptom severity. More significant metabolic changes were found after 8 weeks than 4 weeks post baseline. Within the tryptophan pathway, we noted significant reductions in serotonin (5HT) and increases in indoles that

SUBMITTER: Bhattacharyya S 

PROVIDER: S-EPMC6609722 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature